Pharmacotherapeutic management of asthma in the elderly patient

References

• GINA. Global initiative for asthma. 2019 [cited 2020 Mar 20]. Available from: https://ginasthma.org/
   Google Scholar
• Yernault JC. Dyspnoea in the elderly: a clinical approach to diagnosis. Drugs Aging. 2001;18(3):177–187.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Schivo M, Chan A, et al. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo). 2011;2011:861926.
   PubMedGoogle Scholar
• Yawn BP, Han MK. Practical considerations for the diagnosis and management of asthma in older adults. Mayo Clin Proc. 2017;92(11):1697–1705.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Pedone C, Battaglia S, et al. Diagnosis and management of asthma in the elderly. Eur J Intern Med. 2014;25(4):336–342.
   PubMed Web of Science ®Google Scholar
• Lee E, Kim A, Ye YM, et al. Increasing prevalence and mortality of asthma with age in Korea, 2002-2015: a nationwide, population-based study. Allergy Asthma Immunol Res. 2020;12(3):467–484.
   PubMed Web of Science ®Google Scholar
• Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22–37.
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790–804.
   PubMed Web of Science ®Google Scholar
• Ilmarinen P, Tuomisto LE, Kankaanranta H. Phenotypes, risk factors, and mechanisms of adult-onset asthma. Mediators Inflamm. 2015;2015:514868.
   PubMed Web of Science ®Google Scholar
• Ilmarinen P, Tuomisto LE, Niemela O, et al. Cluster analysis on longitudinal data of patients with adult-onset asthma. J Allergy Clin Immunol Pract. 2017;5(4):967–978. e963.
   PubMed Web of Science ®Google Scholar
• Skloot GS, Busse PJ, Braman SS, et al. An official american thoracic society workshop report: evaluation and management of asthma in the elderly. Ann Am Thorac Soc. 2016;13(11):2064–2077.
   PubMed Web of Science ®Google Scholar
• Bozek A, Filipowski M, Fischer A, et al. Characteristics of atopic bronchial asthma in seniors over 80 years of age. Biomed Res Int. 2013;2013:689782.
   PubMed Web of Science ®Google Scholar
• Toren K, Murgia N, Schioler L, et al. Reference values of fractional excretion of exhaled nitric oxide among non-smokers and current smokers. BMC Pulm Med. 2017;17(1):118.
   PubMedGoogle Scholar
• Malerba M, Damiani G, Carpagnano GE, et al. Values in elderly people for exhaled nitric oxide study. Rejuvenation Res. 2016;19(3):233–238.
   PubMed Web of Science ®Google Scholar
• Hanania NA, King MJ, Braman SS, et al. Asthma in the elderly: current understanding and future research needs–a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(3 Suppl):S4–24.
   PubMed Web of Science ®Google Scholar
• Ulambayar B, Lee SH, Yang EM, et al. Association between epithelial cytokines and clinical phenotypes of elderly asthma. Allergy Asthma Immunol Res. 2019;11(1):79–89.
   PubMed Web of Science ®Google Scholar
• Hsu J, Chen J, Mirabelli MC. Asthma morbidity, comorbidities, and modifiable factors among older adults. J Allergy Clin Immunol Pract. 2018;6(1):236–243 e237.
   PubMed Web of Science ®Google Scholar
• Dunn RM, Lehman E, Chinchilli VM, et al. Impact of age and sex on response to asthma therapy. Am J Respir Crit Care Med. 2015;192(5):551–558.
   PubMed Web of Science ®Google Scholar
• Gemicioglu B, Bayram H, Cimrin A, et al. Asthma control and adherence in newly diagnosed young and elderly adult patients with asthma in Turkey. J Asthma. 2019;56(5):553–561.
   PubMed Web of Science ®Google Scholar
• Bozek A, Jarzab J, Hadas E, et al. Fall episodes in elderly patients with asthma and COPD – A pilot study. J Asthma. 2019;56(6):627–631.
   PubMed Web of Science ®Google Scholar
• Bellia V, Catalano F, Scichilone N, et al. Sleep disorders in the elderly with and without chronic airflow obstruction: the SARA study. Sleep. 2003;26(3):318–323.
   PubMed Web of Science ®Google Scholar
• Diggory P, Heyworth P, Chau G, et al. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye (Lond). 1993;7(Pt 5):661–663.
   PubMedGoogle Scholar
• Diggory P, Heyworth P, Chau G, et al. Unsuspected bronchospasm in association with topical timolol–a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age Ageing. 1994;23(1):17–21.
   PubMed Web of Science ®Google Scholar
• Wardzynska A, Kubsik B, Kowalski ML. Comorbidities in elderly patients with asthma: association with control of the disease and concomitant treatment. Geriatr Gerontol Int. 2015;15(7):902–909.
   PubMed Web of Science ®Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472.
   PubMed Web of Science ®Google Scholar
• Gregoriano C, Dieterle T, Breitenstein AL, et al. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. Respir Res. 2018;19(1):237.
   PubMedGoogle Scholar
• Barbara S, Kritikos V, Bosnic-Anticevich S. Inhaler technique: does age matter? A systematic review. Eur Respir Rev. 2017;26(146):170055.
   PubMed Web of Science ®Google Scholar
• Hira D, Komase Y, Koshiyama S, et al. Problems of elderly patients on inhalation therapy: difference in problem recognition between patients and medical professionals. Allergol Int. 2016;65(4):444–449.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax. 2012;67(3):268–270.
   PubMed Web of Science ®Google Scholar
• Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of compliance and inhaler technique assessments. J Asthma. 2014;51(4):429–434.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Bullick SW, Schivo M, et al. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Des Devel Ther. 2016;10:4047–4060.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Benfante A, Bocchino M, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–67.
   PubMed Web of Science ®Google Scholar
• Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing. 2003;32(3):299–302.
   PubMed Web of Science ®Google Scholar
• Woo SD, Ye YM, Lee Y, et al. Efficacy and safety of a pressurized metered-dose inhaler in older asthmatics: comparison to a dry powder inhaler in a 12-week randomized trial. Allergy Asthma Immunol Res. 2020;12(3):454–466.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest. 1993;104(5):1332–1337.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Fontana GA. Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv. 2009;6(1):91–102.
   PubMed Web of Science ®Google Scholar
• Karamched KR, Hao W, Song PX, et al. The impact of patient autonomy on older adults with asthma. Ann Allergy Asthma Immunol. 2018;121(1):65–68. e61.
   PubMed Web of Science ®Google Scholar
• Boonpiyathad T, Sozener ZC, Satitsuksanoa P, et al. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333.
   PubMed Web of Science ®Google Scholar
• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51.
   PubMed Web of Science ®Google Scholar
• Ban GY, Ye YM, Lee Y, et al. Predictors of asthma control by stepwise treatment in elderly asthmatic patients. J Korean Med Sci. 2015;30(8):1042–1047.
   PubMed Web of Science ®Google Scholar
• Martinez-Moragon E, Delgado J, Mogrovejo S, et al. Factors that determine the loss of control when reducing therapy by steps in the treatment of moderate-severe asthma in standard clinical practice: a multicentre Spanish study. Rev Clin Esp. 2020;220(2):86–93.
   PubMed Web of Science ®Google Scholar
• Rhee CK, van Boven JFM, Yau Ming SW, et al. Does changing inhaler device impact real-life asthma outcomes? Clinical and economic evaluation. J Allergy Clin Immunol Pract. 2019;7(3):934–942.
   PubMed Web of Science ®Google Scholar
• Melani AS. Management of asthma in the elderly patient. Clin Interv Aging. 2013;8:913–922.
   PubMed Web of Science ®Google Scholar
• Agusta F, Battaglia S, Benfante A, et al. Challenges in the pharmacological treatment of geriatric asthma. Expert Rev Clin Pharmacol. 2016;9(7):917–926.
   PubMed Web of Science ®Google Scholar
• Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy. 2018;73(2):284–294.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36–45.
   PubMed Web of Science ®Google Scholar
• Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol Ther. 1993;60(3):389–404.
   PubMed Web of Science ®Google Scholar
• Connolly MJ, Crowley JJ, Charan NB, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest. 1995;108(2):401–406.
   PubMed Web of Science ®Google Scholar
• Kradjan WA, Driesner NK, Abuan TH, et al. Effect of age on bronchodilator response. Chest. 1992;101(6):1545–1551.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Detmar-Hanna D, Zahniser NR. Lack of an effect of age on beta-adrenoceptor-mediated lipolysis in isolated human adipocytes. J Gerontol A Biol Sci Med Sci. 1999;54(2):B71–77.
   PubMed Web of Science ®Google Scholar
• Langin D, Tavernier G, Lafontan M. Regulation of beta 3-adrenoceptor expression in white fat cells. Fundam Clin Pharmacol. 1995;9(2):97–106.
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Rinaldi B. beta2-adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. Curr Opin Pharmacol. 2018;40:142–146.
   PubMed Web of Science ®Google Scholar
• Walters EH, Walters J. Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev. 2000;4:CD001285.
   Google Scholar
• Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al., Group SS. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bateman ED, Caplan AL, et al. Combined analysis of asthma safety trials of long-acting beta2-agonists. N Engl J Med. 2018;378(26):2497–2505.
   PubMed Web of Science ®Google Scholar
• Butland BK, Anderson HR, Cates CJ. Bronchodilator treatment and asthma death: a new analysis of a British case-control study. Respir Med. 2011;105(4):549–557.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Richards JR, Zeki AA. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Ther Adv Respir Dis. 2016;10(1):43–56.
   PubMed Web of Science ®Google Scholar
• Kagohashi K, Satoh H, Ohara G, et al. Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma. Exp Ther Med. 2014;7(4):1005–1009.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Tavakoli H, Lynd LD, et al. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–140.
   PubMed Web of Science ®Google Scholar
• Tavakoli H, Mark FitzGerald J, Lynd LD, et al. Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study. BMC Pulm Med. 2018;18(1):33.
   PubMedGoogle Scholar
• Liem EB, Mnookin SC, Mahla ME. Albuterol-induced lactic acidosis. Anesthesiology. 2003;99(2):505–506.
   PubMed Web of Science ®Google Scholar
• Stratakos G, Kalomenidis J, Routsi C, et al. Transient lactic acidosis as a side effect of inhaled salbutamol. Chest. 2002;122(1):385–386.
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Schwahn B, Schuster A. Hyperlactic acidosis as metabolic side-effect of albuterol and theophylline in acute severe asthma. Klin Padiatr. 2010;222(4):271–272.
   PubMed Web of Science ®Google Scholar
• Gupta P, O’Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging. 2008;25(5):415–443.
   PubMed Web of Science ®Google Scholar
• Magee JS, Pittman LM, Jette-Kelly LA. Paradoxical bronchoconstriction with short-acting beta agonist. Am J Case Rep. 2018;19:1204–1207.
   PubMed Web of Science ®Google Scholar
• Schissler AJ, Celli BR. Prevalence of paradoxical bronchoconstriction after inhaled albuterol. Respir Med. 2018;141:100–102.
   PubMed Web of Science ®Google Scholar
• Gal TJ, Suratt PM, Lu JY. Glycopyrrolate and atropine inhalation: comparative effects on normal airway function. Am Rev Respir Dis. 1984;129(5):871–873.
   PubMedGoogle Scholar
• Johnson BE, Suratt PM, Gal TJ, et al. Effect of inhaled glycopyrrolate and atropine in asthma. Precipitated by exercise and cold air inhalation. Chest. 1984;85(3):325–328.
   PubMed Web of Science ®Google Scholar
• Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf. 2001;24(14):1065–1080.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.
   PubMed Web of Science ®Google Scholar
• Santus P, Centanni S, Verga M, et al. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med. 2006;100(7):1277–1281.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376.
   PubMed Web of Science ®Google Scholar
• Doherty DE, Bleecker ER, Moroni-Zentgraf P, et al. Tiotropium Respimat efficacy and safety in asthma: relationship to age. J Allergy Clin Immunol Pract. 2020. DOI:10.1016/j.jaip.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Lee LA, Briggs A, Edwards LD, et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. Respir Med. 2015;109(1):63–73.
   PubMed Web of Science ®Google Scholar
• Schroeckenstein DC, Bush RK, Chervinsky P, et al. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol. 1988;82(1):115–119.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005;128(4):1974–1979.
   PubMed Web of Science ®Google Scholar
• Taller D, Bender S. Health-related effects of home nebulization with glycopyrronium on difficult-to-treat asthma: post-hoc analyses of an observational study. Interact J Med Res. 2020;9:e17863.
   Google Scholar
• Albertson TE, Chenoweth JA, Adams JY, et al. Muscarinic antagonists in early stage clinical development for the treatment of asthma. Expert Opin Investig Drugs. 2017;26(1):35–49.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Chenoweth JA, Pearson SJ, et al. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). Expert Opin Pharmacother. 2020;21(2):213–231.
   PubMed Web of Science ®Google Scholar
• Dusser D, Ducharme FM. Safety of tiotropium in patients with asthma. Ther Adv Respir Dis. 2019;13:1753466618824010.
   Web of Science ®Google Scholar
• Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25–35.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol. 1998;102(4 Pt 1):531–538.
   PubMed Web of Science ®Google Scholar
• Johansson SA, Dahl R. A double-blind dose-response study of budesonide by inhalation in patients with bronchial asthma. Allergy. 1988;43(3):173–178.
   PubMed Web of Science ®Google Scholar
• Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The fluticasone propionate asthma study group. J Allergy Clin Immunol. 1994;94(4):676–683.
   PubMed Web of Science ®Google Scholar
• Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005;4:CD003135.
   Google Scholar
• Adams NP, Bestall JC, Lasserson TJ, et al. Inhaled fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005;2:CD003135.
   Google Scholar
• McCracken JL, Veeranki SP, Ameredes BT, et al. Diagnosis and management of asthma in adults: a review. JAMA. 2017;318(3):279–290.
   PubMed Web of Science ®Google Scholar
• Anderson WJ, Short PM, Williamson PA, et al. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest. 2012;142(6):1553–1561.
   PubMed Web of Science ®Google Scholar
• Chipps B, Taylor B, Bayer V, et al. Relative efficacy and safety of inhaled corticosteroids in asthma patients: systematic review and network meta-analysis. Ann Allergy Asthma Immunol. 2020. DOI:10.1016/j.anai.2020.04.006.
   Web of Science ®Google Scholar
• Beasley R, Harper J, Bird G, et al. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2019;199(12):1471–1477.
   PubMed Web of Science ®Google Scholar
• Crossingham I, Evans DJ, Halcovitch NR, et al. Stepping down the dose of inhaled corticosteroids for adults with asthma. Cochrane Database Syst Rev. 2017;2:CD011802.
   PubMed Web of Science ®Google Scholar
• Keeley D. Inhaled corticosteroids for asthma: guidance is inconsistent. BMJ. 2019;367:l6934.
   PubMedGoogle Scholar
• Boulet LP, Nair P. Inhaled corticosteroids and adult asthma. Am J Respir Crit Care Med. 2019;200(12):1556–1557.
   PubMed Web of Science ®Google Scholar
• Secombe P, Stewart P, Singh S, et al. Clinical management practices of life-threatening asthma: an audit of practices in intensive care. Crit Care Resusc. 2019;21(1):53–62.
   PubMed Web of Science ®Google Scholar
• Kirkland SW, Cross E, Campbell S, et al. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Cochrane Database Syst Rev. 2018;6:CD012629.
   PubMedGoogle Scholar
• Cooper V, Metcalf L, Versnel J, et al. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15026.
   PubMed Web of Science ®Google Scholar
• Battaglia S, Cardillo I, Lavorini F, et al. Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging. 2014;31(11):787–796.
   PubMed Web of Science ®Google Scholar
• Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, et al. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf. 2008;31(5):409–414.
   PubMed Web of Science ®Google Scholar
• McKeever T, Harrison TW, Hubbard R, et al. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest. 2013;144(6):1788–1794.
   PubMed Web of Science ®Google Scholar
• Bansal V, Mangi MA, Johnson MM, et al. Inhaled corticosteroids and incident pneumonia in patients with asthma: systematic review and meta-analysis. Acta Med Acad. 2015;44(2):135–158.
   PubMedGoogle Scholar
• Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med. 2012;18(1):85–89.
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Wojciechowski P, Dziewonska M, et al. Adrenal suppression by inhaled corticosteroids in patients with asthma: a systematic review and quantitative analysis. Allergy Asthma Proc. 2016;37(1):9–17.
   PubMed Web of Science ®Google Scholar
• Rottenkolber M, Fischer R, Ibanez L, et al. Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial. BMC Pulm Med. 2015;15:55.
   PubMed Web of Science ®Google Scholar
• Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59.
   PubMed Web of Science ®Google Scholar
• Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin. 2007;23(8):1867–1878.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhou X, Wang C, et al. Symbicort(R) Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines. Expert Rev Respir Med. 2018;12(3):191–202.
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485–1496.
   PubMed Web of Science ®Google Scholar
• Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928.
   PubMed Web of Science ®Google Scholar
• Wan Yau Ming S, Haughney J, Small I, et al. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: a real-life effectiveness and cost impact evaluation. Respir Med. 2017;129(199–206). DOI:10.1016/j.rmed.2017.06.016.
   PubMedGoogle Scholar
• Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J Asthma. 2005;42(9):715–724.
   PubMed Web of Science ®Google Scholar
• Aballea S, Cure S, Vogelmeier C, et al. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany. Int J Clin Pract. 2008;62(12):1870–1879.
   PubMed Web of Science ®Google Scholar
• Frois C, Wu EQ, Ray S, et al. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther. 2009;31(12):2779–2803.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–1830.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Blanchette CM, Roberts MH, et al. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population. Am J Geriatr Pharmacother. 2012;10(6):343–351.
   PubMedGoogle Scholar
• Blais CM, Davis BE, Cockcroft DW. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir Res. 2017;18(1):146.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;1:CD011721.
   Google Scholar
• Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–1484.
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Lin CYH, et al. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539–1548.
   PubMed Web of Science ®Google Scholar
• Ishiura Y, Fujimura M, Ohkura N, et al. Effect of triple therapy in patients with asthma-COPD overlap. Int J Clin Pharmacol Ther. 2019;57(8):384–392.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749.
   PubMed Web of Science ®Google Scholar
• Watz H, Mohlfeld JM, Singh D, et al. The combination of indacaterol/glycopyrronium/mometasome furoate is superior to high-dose salmeterol/fluticasone propionate in improving lung function in patients with asthma. Am J Respir Crit Care Med. 2019;199:A7081.
   Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Matera MG, et al. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019;13(11):1079–1085.
   PubMed Web of Science ®Google Scholar
• Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–287.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li B. Effects of montelukast sodium plus budesonide on lung function, inflammatory factors, and immune levels in elderly patients with asthma. Ir J Med Sci. 2020. DOI:10.1007/s11845-019-02167-5
   Web of Science ®Google Scholar
• Sanchez G, Buitrago D. Effect of montelukast 10 mg in elderly patients with mild and moderate asthma compared with young adults. Results of a cohort study. Open Respir Med J. 2018;12:67–74.
   PubMedGoogle Scholar
• Chen CF, Lv Y, Zhang HP, et al. Does zafirlukast reduce future risk of asthma exacerbations in adults? Systematic review and meta-analysis. Multidiscip Respir Med. 2014;9(1):30.
   PubMedGoogle Scholar
• Korenblat PE, Kemp JP, Scherger JE, et al. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol. 2000;84(2):217–225.
   PubMed Web of Science ®Google Scholar
• Creticos P, Knobil K, Edwards LD, et al. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol. 2002;88(4):401–409.
   PubMed Web of Science ®Google Scholar
• Chauhan BF, Jeyaraman MM, Singh Mann A, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev. 2017;3:CD010347.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Boveri B, Carlucci P, et al. Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. Pulm Pharmacol Ther. 2000;13(6):301–305.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Battaglia S, Benfante A, et al. Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. Clin Interv Aging. 2013;8:1329–1337.
   PubMed Web of Science ®Google Scholar
• Law SWY, Wong AYS, Anand S, et al. Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf. 2018;41(3):253–265.
   PubMed Web of Science ®Google Scholar
• Zhou EH, Kaplan S, Mosholder A, et al. Antidepressant medication dispensing among montelukast initiators. J Asthma. 2013;50(9):990–995.
   PubMed Web of Science ®Google Scholar
• Winkel JS, Damkier P, Hallas J, et al. Treatment with montelukast and antidepressive medication-a symmetry analysis. Pharmacoepidemiol Drug Saf. 2018;27(12):1409–1415.
   PubMed Web of Science ®Google Scholar
• Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007;61(4):663–676.
   PubMed Web of Science ®Google Scholar
• Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1187–1194.
   PubMed Web of Science ®Google Scholar
• Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996;275(12):931–936.
   PubMed Web of Science ®Google Scholar
• Steinke JW, Culp JA. Leukotriene synthesis inhibitors versus antagonists: the pros and cons. Curr Allergy Asthma Rep. 2007;7(2):126–133.
   PubMed Web of Science ®Google Scholar
• Kubavat AH, Khippal N, Tak S, et al. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther. 2013;20(2):154–162.
   PubMed Web of Science ®Google Scholar
• Magazine R, Shahul HA, Chogtu B, et al. Comparison of oral montelukast with oral zileuton in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India. 2016;33(3):281–286.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–906.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin K, Wang C, et al. Addition of theophylline or increasing the dose of inhaled corticosteroid in symptomatic asthma: a meta-analysis of randomized controlled trials. Yonsei Med J. 2011;52(2):268–275.
   PubMed Web of Science ®Google Scholar
• Mahemuti G, Zhang H, Li J, et al. Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:99–120.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Hanania NA, Dini FL, et al. Impact of doxofylline compared to theophylline in asthma: a pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018;53:20–26.
   PubMed Web of Science ®Google Scholar
• Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma – a double-blind randomized placebo-controlled multicentre clinical trial. Med Sci Monit. 2002;8(4):CR297–304.
   PubMedGoogle Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329.
   PubMed Web of Science ®Google Scholar
• Johnston SL, Szigeti M, Cross M, et al. Azithromycin for Acute Exacerbations of Asthma: the AZALEA Randomized Clinical Trial. JAMA Intern Med. 2016;176(11):1630–1637.
   PubMed Web of Science ®Google Scholar
• Taylor SL, Leong LEX, Mobegi FM, et al. Long-term azithromycin reduces haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med. 2019;200(3):309–317.
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang L, Yang J, et al. Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: a systematic review and meta-analysis. Respirology. 2018;23(5):467–477.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen Y, Fan L, et al. Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap. Drug Des Devel Ther. 2018;12:2371–2379.
   PubMed Web of Science ®Google Scholar
• Bardin P, Kanniess F, Gauvreau G, et al. Roflumilast for asthma: efficacy findings in mechanism of action studies. Pulm Pharmacol Ther. 2015;35(Suppl):S4–10.
   PubMedGoogle Scholar
• Al-Sajee D, Yin X, Gauvreau GM. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma. Expert Opin Pharmacother. 2019;20(5):609–620.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35(Suppl):S20–27.
   PubMedGoogle Scholar
• Bateman ED, Bousquet J, Aubier M, et al. Roflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studies. Pulm Pharmacol Ther. 2015;35(Suppl):S11–19.
   PubMedGoogle Scholar
• Bateman ED, Goehring UM, Richard F, et al. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016;138(1):142–149. e148.
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Meltzer EO, Busse W, et al. Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies. Pulm Pharmacol Ther. 2015;35(Suppl):S28–34.
   PubMedGoogle Scholar
• Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017;5(11):881–890.
   PubMed Web of Science ®Google Scholar
• Li WF, Huang YQ, Huang C, et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: an updated systematic review and meta-analysis of observational studies. Oncotarget. 2017;8(42):73000–73008.
   PubMedGoogle Scholar
• Zhang W, Zhang Y, Li CW, et al. Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest. 2017;152(6):1159–1168.
   PubMed Web of Science ®Google Scholar
• Yeh JJ, Syue SH, Lin CL, et al. Statin use and vital organ failure in patients with asthma-chronic obstructive pulmonary disease overlap: a time-dependent population-based study. Front Pharmacol. 2019;10:889.
   PubMed Web of Science ®Google Scholar
• Yeh JJ, Syue SH, Lin CL, et al. Effects of statins on anxiety and depression in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. J Affect Disord. 2019;253:277–284.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Oldham J, Wilson M, et al. Statin use and asthma control in patients with severe asthma. BMJ Open. 2013;3:8.
   Web of Science ®Google Scholar
• Zeki AA, Elbadawi-Sidhu M. Innovations in asthma therapy: is there a role for inhaled statins? Expert Rev Respir Med. 2018;12(6):461–473.
   PubMed Web of Science ®Google Scholar
• Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18(7):747–754.
   PubMed Web of Science ®Google Scholar
• Milger K, Korn S, Buhl R, et al. Age- and sex-dependent differences in patients with severe asthma included in the German asthma net cohort. Respir Med. 2020;162:105858.
   PubMed Web of Science ®Google Scholar
• Akenroye A, McCormack M, Keet C. Severe asthma in the US population and eligibility for mAb therapy. J Allergy Clin Immunol. 2020;145(4):1295–1297 e1296.
   PubMed Web of Science ®Google Scholar
• Rubinsztajn R, Chazan R. Monoclonal antibodies for the management of severe asthma. Adv Exp Med Biol. 2016;935:35–42.
   PubMed Web of Science ®Google Scholar
• Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014;20(1):87–94.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Korn S, Schumann C, Kropf C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105(4):313–319.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Latorre M, et al. Effects of omalizumab in severe asthmatics across ages: a real life Italian experience. Respir Med. 2016;119:141–149.
   PubMed Web of Science ®Google Scholar
• Maykut RJ, Kianifard F, Geba GP. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. J Asthma. 2008;45(3):173–181.
   PubMed Web of Science ®Google Scholar
• Tat TS, Cilli A. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Ann Allergy Asthma Immunol. 2016;117(5):546–549.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Numata T, Nakayama K, Utsumi H, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulm Med. 2019;19(1):176.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141.
   PubMed Web of Science ®Google Scholar
• Saco TV, Pepper AN, Lockey RF. Benralizumab for the treatment of asthma. Expert Rev Clin Immunol. 2017;13(5):405–413.
   PubMed Web of Science ®Google Scholar
• Casale TB, Pacou M, Mesana L, et al. Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1):122–130 e121.
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200. e120.
   PubMed Web of Science ®Google Scholar
• Santini G, Mores N, Malerba M, et al. Dupilumab for the treatment of asthma. Expert Opin Investig Drugs. 2017;26(3):357–366.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Heffler E, Testino E, et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019;15(2):113–120.
   PubMed Web of Science ®Google Scholar
• Yan L, Wang B, Chia YL, et al. Population pharmacokinetic modeling of benralizumab in adult and adolescent patients with asthma. Clin Pharmacokinet. 2019;58(7):943–958.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rinaldi B, et al. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2017;13(9):1007–1013.
   PubMed Web of Science ®Google Scholar
• Iftikhar IH, Schimmel M, Bender W, et al. Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung. 2018;196(5):517–530.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol. 2019;15(6):517–520.
   PubMed Web of Science ®Google Scholar
• Edris A, De Feyter S, Maes T, et al. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179.
   PubMed Web of Science ®Google Scholar
• Benfante A, Principe S, Battaglia S, et al. Are biological drugs effective and safe in older severe asthmatics? Expert Opin Drug Saf. 2019;18(5):369–380.
   PubMed Web of Science ®Google Scholar